Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

I 100% agree with bio48. Stop the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Lakersrback Member Profile
 
Followed By 2
Posts 398
Boards Moderated 1
Alias Born 08/29/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/20/2022 4:32:05 PM
Leerink Partners Thinks Cytosorbents’ Stock is Going to Recover TipRanks - 1/20/2022 3:46:07 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/18/2022 4:32:30 PM
CytoSorbents jumps 1.86% on prelim FY21 and Q4 revenue above the consensus Seeking Alpha - 1/18/2022 7:35:44 AM
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue PR Newswire (US) - 1/18/2022 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/7/2022 5:11:35 PM
Dawson James Remains a Buy on Cytosorbents (CTSO) TipRanks - 1/5/2022 4:10:04 AM
Dawson James Sticks to Their Buy Rating for Cytosorbents (CTSO) TipRanks - 1/5/2022 4:08:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2021 5:29:04 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/30/2021 5:27:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2021 9:01:13 AM
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular PR Newswire (US) - 12/21/2021 7:05:00 AM
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire (US) - 12/20/2021 7:10:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/13/2021 5:01:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2021 9:06:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 6:11:44 PM
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference PR Newswire (US) - 11/15/2021 4:30:00 PM
Cytosorbents EPS misses by $0.03, beats on revenue Seeking Alpha - 11/4/2021 4:29:11 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2021 4:15:41 PM
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results PR Newswire (US) - 11/4/2021 4:15:00 PM
Cytosorbents Q3 2021 Earnings Preview Seeking Alpha - 11/3/2021 5:35:41 PM
CytoSorbents Comments on REMOVE Study Presentation PR Newswire (US) - 10/20/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2021 6:26:17 AM
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery PR Newswire (US) - 10/14/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2021 7:01:40 AM
Lakersrback   Tuesday, 10/19/21 01:54:33 PM
Re: None
Post # of 27006 
I 100% agree with bio48. Stop the silly talk of management being the problem. How about the actual product? How is it really performing? Based the FDA trial experience to this point, we do not really know do we?

Blaming management is a masking mechanism. The product itself needs some FDA data to back it's efficacy. I don't believe the CE mark required anything more than a safety check. I believe that the constant attacks on management deflect the fact that there is very little proof as to exactly how well this filter works. Fresenius were involved in Europe years back but left the relationship. Supposedly they are involved in Mexico or something. What are the sales numbers through Fresenius. This would be very telling. The fact that a companion diagnostic is not available to confirm what is said to be happening allows for a continuation of speculation. I'm looking to sell the last few I have and move on.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences